|To: StockDung who wrote (925)||12/18/2004 1:02:38 PM|
|Gayle is a punk. His involvement internally at GIFS is well known. I have some documents regarding his communications...(s)|
When GIFS was about to crumble and he was provided with the truth, he completely ignored it because he was invested and involved...
So, then the articles started about me being a jewel thief, corporate spy, on my way to Mexico...lolol...instead the offices at GIFS were raided and the company was shut down.
Zayed and Gayle were tight...
|RecommendKeepReplyMark as Last ReadRead Replies (1)|
|To: tonto who wrote (932)||12/18/2004 1:11:17 PM|
|Re - MORE INFO ON GAYLE ESSARY COMES TO LIGHT |
To: TheTruthseeker who wrote (88832) 12/18/2004 12:05:16 PM
From: scionist Read Replies (1) of 88852
Re - MORE INFO ON GAYLE ESSARY COMES TO LIGHT
10. Plaintiff Mark F. Backhaus purchased shares of Streamedia common stock pursuant to the Company’s Prospectus filed in connection with its IPO, which was commenced on December 22, 1999. His signed certification, executed pursuant to the federal securities laws, is attached hereto.
11. Streamedia is a Delaware corporation that claims to provide website owners and content publishers with cost-effective services and tools for streaming, or broadcasting, live and on demand video and audio content over the Internet. The Company also operates a so-called .broadcast content website,. Bijou Cafe, at www.bijoucafe.com. The Company claims to have two primary components: it acts as an Internet content publisher and broadcaster, and as a business-to-business service bureau, to assist other businesses to publish and broadcast their content on the Web.
12. Defendant James D. Rupp ("Rupp") was the President and Chief Executive Officer and a director of the Company from its inception until October of 2000, when he resigned his management role, though he continued to serve as a director. In addition, Rupp signed the Prospectus filed in connection with the Company’s IPO. Rupp has been President and CEO of Capital Markets Communications Corporation a publisher of a number of Internet micro-cap stock
promotion newsletters including StreetSignals, TradeSignals, PowerSignals, AmexWire and the Waaco Kid.s Forum, among others.
13. Defendant Gayle Essary (.Essary.) was a founder, the Chairman and Vice President of the Company from its inception until his termination by the Company in March of 2001. In addition, Essary signed the Prospectus filed in connection with the Company’s IPO. Essary has also been Chairman of Investors Research Institute, an organization aimed at promoting the stock of microcap companies to individual investors. He is, and has been, an executive officer of several other companies that operate Internet stock promotion newsletters including HotStocks@StreetLevel, the Waaco Kid.s Forum and a number of others.
14. Defendant Walter Hollenberg ("Hollenberg") was the Vice President of Technology for Streamedia from July 1999 until sometime in 2000 and is listed in the Prospectus as an executive officer of the Company.
15. Defendant Nicholas Malino ("Malino") was the Chief Financial Officer of the Company beginning in November of 1998 and also served as Executive Vice President and Chief Operating Officer from August of 1999 until his resignation in October of 2000. In addition, Malino signed the Prospectus filed in connection with the Company’s IPO.
16. Defendant Henry Siegel (.Siegel.) was at all relevant times a director of the Company and in October of 2000, Seigel became the Chief Executive Officer of the Company. In addition,
Seigel signed the Prospectus filed in connection with the Company’s IPO.
17. Defendants Robert J. Wussler and David J. Simonetti were, at all relevant times, directors of Streamedia, and they each signed the Prospectus filed in connection with the Company’s IPO.
18. For purposes of this Complaint, the individual defendants identified in ¶¶12-17 shall be referred to herein as the "Individual Defendants."
19. Defendant Capital West Securities, Inc. (.Capital West.) is an Oklahoma corporation principally located at 211 North Robinson Street, Suite 200, Oklahoma City, OK, 73102-7101. Capital West is an NASD registered broker/dealer and acted as a lead underwriter and as corepresentative
for the underwriting group in the IPO.
20. Defendant Institutional Equity Corporation (.IEQ.) is an Oklahoma corporation principally located at 5910 North Central Expressway Ste. 1480, Dallas, TX 75206. IEQ is an NASD registered broker/dealer and acted as a lead underwriter and as co-representative for the underwriting group in the IPO.
21. Defendant Kashner Davidson Securities Corporation (.Kashner.) is a Florida corporation principally located at 77 South Palm Avenue, Sarasota, FL 34236-7724. Kashner is an NASD registered broker/dealer and acted as an underwriter for the IPO.
22. Defendant Nutmeg Securities, Ltd. (.Nutmeg.) is a Connecticut corporation principally located at 495 Post Road East, Westport, Ct 06880. Nutmeg is an NASD registered broker/dealer and acted as an underwriter for the IPO.
23. Defendant Schneider Securities, Inc. (.Schneider.) is a Colorado corporation principally located at 1120 Lincoln Street, Suite 900, Denver, CO, 80203. Schneider is an NASD registered broker/dealer and acted as an underwriter for the IPO.
24. Defendant Westport Resources Investment Services, Inc. (.Westport.) is a Connecticut corporation principally located at 315 Post Road West, Westport, CT 06880-4645. Westport is an NASD registered broker/dealer and acted as an underwriter for the IPO.
25. Defendant The Agean Group, Inc. (.Agean.) is a Florida corporation principally located at One South Ocean Blvd. Suite 300, Boca Raton, FL, 33432. Agean is an NASD registered broker/dealer and acted as an underwriter for the IPO.
26. Defendant Smith, Moore & Co. (.Smith.) is a Missouri corporation principally located at 400 Locust Street, St. Louis, MO 63102. Smith is an NASD registered broker/dealer and acted as an underwriter for the IPO.
27. Defendant Global Capital Securities Corporation, formerly known as EBI Securities Corporation (.Global.) is a Missouri corporation principally located at 6300 South Syracuse Way, Suite 645, Englewood, CO, 80111. Global is an NASD registered broker/dealer and acted as an underwriter for the IPO.
28. For purposes of this Complaint, defendants Capital West, IEQ, Nutmeg, Kashner, Westport, Schneider, Agean, Smith and Global will be referred to herein as the "Underwriter Defendants."
29. The Underwriter Defendants were the underwriters for the IPO, and were primarily involved in offering and selling shares of the Company to the public in the IPO.
|RecommendKeepReplyMark as Last ReadRead Replies (1)|
|To: scion who wrote (935)||12/18/2004 1:41:05 PM|
|lol. Essary would talk big through his "media empire", but then would cry about his old beater that he had to drive and he did not want his children to learn through the internet what he truly is...|
|RecommendKeepReplyMark as Last Read|
|To: afrayem onigwecher who wrote (931)||12/29/2004 10:46:57 AM|
|.IN THE MONEY: GeneMax Naked-Short Suits Dismissed|
28 December 2004
Dow Jones News Service
(c) 2004 Dow Jones & Company, Inc.
By Carol S. Remond
A Dow Jones Newswires Column
NEW YORK (Dow Jones)--Two more lawsuits alleging illegal short selling
by brokerage firms have been dismissed without much fanfare.
Biotech company GeneMax Corp. (GMXX) was at the forefront of companies
protesting what they said were unfair attacks by short sellers in late
2002. Back then and through much of 2003, GeneMax and its then-marketing
firm Investor Communications International, or ICI, led a campaign
against naked short selling, or short selling without first borrowing
securities to make delivery.
As part of its campaign, GeneMax filed lawsuits in Canada and in the
U.S. to try to prevent brokerage firms from engaging in naked short
GeneMax filed a lawsuit against Canadian brokerage firms Global
Securities Corp. and Union Securities Corp. in September 2002 in the
Supreme Court of British Columbia. The company alleged that the
brokerages engaged in illegal short selling to manipulate the price of
A court order obtained by Dow Jones Newswires shows that suit was
dismissed on Dec. 16. A countersuit filed by Global Securities and Union
Securities was also dismissed.
GeneMax had widened its legal fight with the brokers to U.S. courts in
October 2002 when it filed suit against 11 brokerage firms in the U.S.
District Court for the District of Nevada. That suit was dismissed. But
the company filed another suit in November 2003 that mirrored much of
the illegal short selling allegations it made in its first Nevada suit,
including fraud and racketeering. The original suit named Knight Trading
Group Inc. (NITE), Charles Schwab Corp. (SCH) and nine others and seeks
injunctions to prevent the firms from shorting GeneMax shares and
Court documents show that the 2003 Nevada suit was dismissed on Nov. 9.
GeneMax's shares, which topped $20 a share in late 2002, are now trading
at a mere 24.5 cents in very thin trading.
GeneMax's President and Chief Executive Ronald Hanford wasn't
immediately available to comment.
GeneMax was the subject of three "In The Money" columns in 2002 and
2003. Those columns questioned whether insiders would benefit most from
limits on short selling and GeneMax's connection to consultant ICI.
GeneMax terminated its agreement with ICI in late 2003.
In a short sale, a security not owned by the seller is sold in
anticipation of a decrease in the stock's price. In the U.S., NASD
requires that before they engage in short sales for themselves or
clients, firms make an affirmative determination that they can borrow a
security or will be able to provide it for delivery on demand. Market
makers are exempt from the affirmative determination rule when engaged
in "bona fide market making activity" because they provide needed
liquidity to the market. Earlier this year, NASD tightened its
affirmative determination rule, making it harder for Canadian brokerages
to take advantage of the fact that no borrowing requirement exists in
In September, another suit alleging naked short selling was dismissed
after Jag Media Holdings Inc. (JAGH), which also led the charge against
naked short selling in the U.S., failed to make its case.
Jag Media and Gary Valinoti, the company's former chief executive, sued
more than 100 brokerage firms, investment firms and financial
institutions in July 2002, alleging that they entered into a civil
conspiracy and concert of action to short sell Jag Media's stock. In the
suit, originally filed in the Judicial District Court, Harris county in
Texas and later removed to the U.S. District Court for the Southern
District of Texas, Houston Division, Jag Media alleged that the
financial institutions committed market manipulation and fraud and
violated securities laws.
That case was dismissed by U.S. District Judge Vanessa Gilmore after she
found multiple deficiencies in Jag Media's third amended complaint.
Gilmore found that Jag Media didn't have a viable claim against those
(Carol S. Remond is an award-winning columnist and one of four who write
the "In The Money" feature. Most recently, she shared a 2003 Best of
Business Award from the Society of American Business Editors and Writers
for her role in Dow Jones' team coverage of the Canary Capital mutual
fund trading scandal.)
-By Carol S. Remond; Dow Jones Newswires; 201 938 2074;
firstname.lastname@example.org [ 12-28-04 1742ET ]
|RecommendKeepReplyMark as Last Read|
|To: afrayem onigwecher who wrote (931)||12/29/2004 11:37:31 AM|
|DAVIDSON CLAIMS SEC LEAKED INFO TO CAROL REMOND. LOL|
"In this respect, it is suggestive that the SEC apparently leaked its complaint about Agora to Remond, who cooperated by writing a story trumpeting the SEC's effort to discredit me and these good companies."
Dear Vantage Point Investor,
You may be as startled and upset as I am by the sudden collapse in the price of GeneMax (GMXX), which has tumbled in the last nine trading days. The question is, why? I can't pretend that I fully understand the answer. But I have a disturbing guess. It appears that the naked short-sellers who have counterfeited millions of GeneMax shares in an attempt to destroy the company have enlisted powerful help.
In theory, the Securities and Exchange Commission is a regulatory body charged with maintaining the integrity of public securities markets in the United States. In reality, the SEC is like any other government agency. It responds to powerful entrenched interests. It abhors bad publicity, rewards its friends and punishes its critics.
Unhappily, the SEC also lies. I know because the SEC field office in Utah has lied about me. And I suspect that these lies are the culmination of a carefully laid plan to discredit GeneMax and punish the company for raising troublesome issues about naked short selling, which has also embarrassed the SEC.
If you have been a subscriber to Vantage Point for any length of time, you are no doubt aware that I am a critic of "electronic counterfeiting," the process by which some investment banks, market makers and broker-dealers drive down the prices of Nasdaq Bulletin Board companies by selling unlimited quantities of shares they don't own. Since stock prices are determined by supply and demand, allowing unlimited counterfeiting of stock essentially guarantees that the stock becomes worthless.
Of course, a company whose shares are worthless won't last long. It is unable to raise money if its stock is worthless. All too often, such small companies are driven into oblivion by electronic counterfeiting. When we are slogging along with a weak economy, I consider it almost criminal negligence that the government would permit investment banks, market makers and broker-dealers to weaken the economy further by destroying small companies that could otherwise be a major fountain of growth.
Why would the government let this happen? I don't think it is necessarily a Grand Conspiracy with a capital "G." But the bad guys have managed to control most of the news about "electronic counterfeiting." And perversely, they also seem to have the regulators on their side.
I had a painful lesson in this reality at the beginning of this week when I learned to my astonishment that the Utah office of the SEC had tarnished my name by accusing me of failing to disclose an interest in two investments that I recommended in Vantage Point Investment Advisory. Their exact charge is as follows:
"Among the issuers promoted in this manner have been GeneMax Corp. and Endovasc Ltd., Inc. DAVIDSON is an officer, director and, indirectly, a substantial shareholder of these two issuers. Neither the soliciting e-mail nor the subsequent company report discloses DAVIDSON's relationship to the companies."
This is total rubbish. I deny any impropriety. Indeed, the charges are remote from the facts.
As you will know if you subscribed to Vantage Point last summer, I fully disclosed my role as a founder, director and officer of GeneMax when I recommended the company and its promising treatment for cancer. And I also disclosed a special relationship with Endovasc. I am not an officer or director of Endovasc. I have a few shares that I received in exchange for assigning my rights in what could be a valuable patent to the company.
To be sure that I wasn't missing something, I had my attorney review the record. He concluded that my disclosures are complete: "I spent this afternoon reviewing Agora marketing copy for Vantage Point and the newsletters and have verified that the charge that you failed to disclose your personal interest in GeneMax is completely false." Agora will be filing a motion to dismiss the SEC's baseless complaint.
I fail to see how anyone of good faith who reviewed the record could possibly construe it as the SEC apparently has. Although I can't prove it, I have concluded that the SEC, or at least some of its personnel, were more offended by my criticism of electronic counterfeiting than they are by the abuse itself -- which causes you and other investors hundreds of billions in losses. In fact, the costs of electronic counterfeiting are much higher than those entailed in the accounting scandals which have garnered so much attention. Nonetheless, instead of correcting these abuses, the SEC has gone out of its way to rope me into a doubtful complaint that they have developed against another Agora publication -- a product to which I have no connection other than a passive one as a minority shareholder in Agora.
Nor do I take it to be entirely a coincidence that while I have recommended more than 30 investments in Vantage Point over the past 16 months, my reputation is being tarred in respect to just two companies, GeneMax and Endovasc. These two companies have one thing in common, in addition to the fact that both have promising medical innovations that could ease much suffering and save many lives. Both have been at the forefront of legal action to combat the abuse of electronic counterfeiting of their shares. But these efforts have hardly earned them the friends they should. Rather than garnering applause, their efforts to confront the abuse of electronic counterfeiting of their shares has made both companies the focus of negative publicity.
In particular, one writer, Carol S. Remond, undertook to paint a negative picture of both companies, publishing what bordered on outright lies. For some reason known only to others, the SEC appears to have adopted Remond's text in defense of the electronic counterfeiters. In this respect, it is suggestive that the SEC apparently leaked its complaint about Agora to Remond, who cooperated by writing a story trumpeting the SEC's effort to discredit me and these good companies.
I wanted to write to you immediately when I got this startling news to tell you that I will not be cowed by these Machiavellian tactics. I will continue to raise important issues of investor protection that the SEC appears to wish to duck. I do so with faith that the truth will eventually triumph, the evil of electronic counterfeiting will be curtailed, and the integrity of public security markets restored.
Or to put it another way, if powerful people are so keen to discredit my criticism of electronic counterfeiting that they will orchestrate an entirely bogus charge of the kind carried on the wires against me this week, that itself indicates that more light needs to be shed on the shadowy activities they are trying to protect.
But, on to the status of your GeneMax holdings... Absolutely nothing about this company or its exciting immunotherapy development has changed and would warrant this share price decline. In fact, in an independent study commissioned by the company, it was determined that if GeneMax were funded as low as at $1.50 per share, and assuming that its products prove to work as well in humans as they have in animals, the present value of the stock would be $420 per share, notwithstanding dilution. GeneMax remains a fundamentally sound company and a tremendous buying opportunity at these levels. I recommend that you increase your GeneMax shares, as well as those in Endovasc (EVSC.OB). And, may I reiterate, I am a shareholder in both companies.
And, if you are as concerned as I am about electronic counterfeiting and its effects on the dynamic young companies that must fuel our country's future growth (as well as your portfolio), I urge you to write your congressman. You can also register your concern with the National Association Against Naked Short Selling (http://www.nakedshortselling.com),, which is taking up the fight for companies and investors alike.
|RecommendKeepReplyMark as Last Read|
|To: scion who wrote (935)||3/5/2005 3:44:55 PM|
|BCSC not pursuing Nano World ex Hunter|
2005-03-04 14:25 ET - Street Wire
by Stockwatch Business Reporter
The B.C. Securities Commission, in its pending hearing for Nano World Projects Corp. and its president, Robert Papalia, is not pursuing former Nano World president David Hunter. Mr. Papalia blamed Mr. Hunter for landing the company in trouble with the U.S. Securities and Exchange Commission and even sued him in B.C. Supreme Court.
The BCSC goes after Nano World
The BCSC has scheduled a hearing for March 7 to try Mr. Papalia and Nano World for allegedly pumping the company with misleading news. The local regulator says Mr. Papalia and Nano World misled investors with false news releases claiming the company had two big deals in Europe.
Nano World, at the time, traded on the lightly regulated, but heavily prosecuted OTC Bulletin Board.
According to the BCSC, Mr. Papalia began issuing the misleading news releases on Sept. 12, 2000, in which he touted deals with Italian automotive giant Fiat and printing company Euroinks (pronounced Euro-inks, not Eur-oinks).
To back up these purported deals, the BCSC says Mr. Papalia issued further news claiming another OTC-BB company, Frefax Inc., was going to provide a loan.
The BCSC alleges that Mr. Papalia sold at least 300,000 shares of Nano World between January and February, 2001, for proceeds of up to $130,000.
The SEC goes after Mr. Papalia
The BCSC was not the first regulator to target Mr. Papalia for the Nano World promotion. The SEC, in a civil action, won a permanent ban against Mr. Papalia on Sept. 1, 2004, for his Nano World shenanigans.
In that case, Judge Marsha Pecham of the United States Federal District Court in Seattle found that Mr. Papalia pumped Nano World up to $24.50 using misleading or false news releases.
In a 15-page judgment she said, "Papalia's violation involved fraud, deceit, manipulation, or deliberate and reckless disregard of a regulatory requirement." In addition to the permanent ban, Judge Pecham fined Mr. Papalia $33,000.
Mr. Papalia, in a statement of defence, denied the SEC's accusations.
The SEC goes after Mr. Hunter
The SEC also named Mr. Hunter in the same civil action as Mr. Papalia. The U.S. regulator said Mr. Hunter misled Nano World investors with false news releases.
Mr. Hunter, who denied the SEC's allegations, settled with the U.S. regulator out of court. He agreed to a five-year ban from the markets and to an injunction barring future U.S. Securities Act violations. He did not admit to any wrongdoing in reaching the settlement.
Mr. Howe Street
David Hunter -- son of Ben, brother of Dan, father of five -- has spent much of his life up to his eyeballs in penny stocks. Many of them have gone to many dollars, and most have ended back where they began. Although Mr. Hunter has not been accused by the BCSC of any Nano World wrongdoing, Mr. Papalia alleged halfheartedly in a very brief lawsuit that Mr. Hunter was at least partly responsible for the company's trouble.
Mr. Papalia sued Mr. Hunter in B.C. Supreme Court on Aug. 16, 2002, on behalf of Nano World. In his self-filed writ, Mr. Papalia said Mr. Hunter misappropriated Nano World's money.
The case never made it before a judge. Mr. Papalia did not follow up his writ a formal statement of claim, which would have provided details, if not credibility, to the allegations against his former colleague. Mr. Hunter did not file a statement of defence.
Mr. Hunter landed at Nano World 10 days after leaving the Vancouver brokerage industry on March 31, 2000. His 25-year brokerage career began in 1975 and included stints at four Vancouver brokerages.
Mr. Hunter's last job in the brokerage industry was at Mark Valentine's Thomson Kernaghan, which he left on March 31, 2000. Prior to Thomson Kernaghan, Mr. Hunter worked at Canaccord Capital Corp. between Sept. 2, 1992, and Jan. 15, 1996. When David and brother Dan arrived at Canaccord from Yorkton Securities, David said: "Our style is probably more like that of venture capitalists/merchant bankers. We try to identify situations, especially junior industrials, that have merit."
During his years as a big-producing broker, seeking those junior industrials of merit, Mr. Hunter introduced some of the players in Brent Pierce's Ultra Pure Water Systems (Canada) Inc., a promotion that left seven brokerages with $2.36-million in unpaid debits. Stephen Taub, a key broker in the case, said he was introduced to two of Ultra Pure's founders, Louis Gorusch and Grant Atkins, by the Hunters.
Mr. Hunter and his brother were also parties of interest, but not suspects or targets, in the SEC's civil prosecution of Dimples Group Inc., a raucous Vancouver Stock Exchange diaper promotion of the early 1990s that ended up covered like most diapers.
Other enterprises of merit that Mr. Hunter was involved with included Cost Miser Coupons (International) Inc. and, a rare success, PLC Systems Inc.
Mr. Hunter could not be reached for comment on Nano World or any other matters. He was last thought to be in Mexico. Mr. Hunter's lawyer in the U.S. case, John Payseno, said he was too busy to comment on the matter.
The BCSC, for its part, says it is aware of Mr. Hunter's involvement with Nano World.
The commission's hearing against Mr. Papalia and Nano World is set to kick off Monday, March 7.
|RecommendKeepReplyMark as Last Read|
|From: StockDung||3/22/2005 12:56:56 PM|
|A Silver Bullet That Conquers Nature's Deadliest Disease Is|
About to "Go Public"
Now There Is Only a Brief Window -
Perhaps Just Weeks - Before These
Shares Blast Off
A small U.S. company - already raking in revenues of more than $1 billion and showing net profits of over $150 million - will post explosive gains in both sales and profits in the weeks ahead. Those who own the stock are - in effect - holding a winning lottery ticket.
1.3 million Americans are diagnosed with cancer each year. And, sadly, more than 1,500 people in the U.S. die from it every day.
But one company is doing something about it. No... not a biotech company hoping to make it through Phase III trials, but rather a medical technology firm whose products are actually killing cancer tumors right now in hundreds of hospitals around the world.
How? With a new cutting-edge technology only recently unveiled. And investors who hold this stock are ready to collect the payoff of a lifetime.
Just listen to what the experts have to say about this company's technology:
* The medical director at the Alta Bates Comprehensive Cancer Center in Berkeley, California says "a quarter or possibly a third of our cancer patient population will soon be undergoing this treatment."
* Another prominent doctor at the University of Texas M.D. Anderson Cancer Center says he intends to treat over 1,000 patients a year with this technology. And, he adds, "it is very much a part of our future."
* And the Professor of Oncology at the University of Michigan, says this breakthrough technology has opened up nothing less than "extraordinary possibilities."
Yet most folks on Wall Street are still unaware of this story. Few investment firms even follow the stock.
But it's just a matter of time before the national media seizes on what's happening here... and turns this unknown company into a household name. Then millions of individual investors - and their fund managers - will begin shoveling money into the stock.
When the public finally understands this company is actually killing cancer tumors right now with a success rate as high as 96%, shares of this company will simply ignite. And, quite frankly, there is no calculating how high the stock will go.
"When the public finally understands this company is actually killing cancer tumors right now with a success rate as high as 96%, shares of this company will simply ignite."
Even the U.S. government has given this new technology its blessing. How can we be sure? Because the company's cancer treatments have just become eligible for both Medicare and Medicaid reimbursement.
Before long, cancer patients the world over will be demanding this medical treatment. And that will spark interest in the stock by investors all over the globe.
That's why I'm contacting you now.
The Sound of Opportunity Knocking . . .
My name is James Boxley Cooke. I'm a former executive of T. Rowe Price.
I'm retired and no longer in the mutual fund business, however. Today I serve as the Chairman of the Board of Governors of the world's largest private financial fellowship. And, quite frankly, my position as head of one of the world's most powerful investment groups gives me access to intelligence and ideas the average investor never hears about.
Our results are nothing short of stellar. Of the 35 current positions in our Trading Portfolio, 29 are profitable, for example.
And recently some members have taken the opportunity to lock in phenomenal short-term profits. Just a brief sampling of our recent winners include:
* 293% in nine weeks in a company that makes nutritional supplements for infant formula.
* 222% in four months in the world's largest web-based auctioneer.
* 433% in ten weeks in an Israeli manufacturer of generic pharmaceuticals.
* 485% in seven weeks in a conservative educational publisher.
* 296% in 27 days in a private, post-secondary education company.
* 180% in two weeks in a leading prison privatization company.
* And 1,385% in a diversified information management systems company. (That's right. Our investment rose more than thirteen-fold in just three months.)
I need hardly remind you that the market's return this year has been a small fraction of this.
Our secret? My group's gains are the result of private connections and top-notch investment intelligence. This allows us access to a steady supply of unusual and highly profitable investment opportunities. But none surpasses the potential of the medical technology company I'm going to tell you about now.
If your portfolio has been damaged by the bear market of the last three years - or you feel like your investments are just treading water - take heart. Because this opportunity has the potential to create life-changing results for you and your family.
This medical technology company meets every one of our criteria for phenomenal returns: cutting-edge products, soaring revenues, blockbuster earnings growth and an enormous new market for its products.
This, in fact, may be the best single-stock opportunity I've seen in my lifetime as an investor. And I've been in the business for over 45 years.
That's why I'm contacting you now. Because if time was ever of the essence, it's now...
Why Early Investors Will Make a Fortune
Let me begin by showing you the immense potential behind this groundbreaking medical technology.
$60 billion is spent on cancer treatment in the U.S. each year. That's right... each year.
Cancer is our country's most notorious killer. There is not a family in this nation that has not been touched in some way by this dreaded disease.
The American Cancer Society estimates that 1.2 million new cancer cases are diagnosed each year. And the total number of cancer cases rises 3% a year in this country.
You don't have to be Isaac Newton to figure out that with baby boomers steadily aging - and increasing their susceptibility to cancer - this company's future growth is assured.
The company is already growing by leaps and bounds right now. That's because this life-saving technology is being used to treat cancers of the head and neck, prostate cancer, pancreatic cancer, spinal cancer, throat cancer, uterine cancer and non-Hodgkin's lymphoma.
There is well-founded speculation that the company may soon get FDA approval to treat breast and lung cancer as well. When it does - and I'm expecting an announcement any day now - it's going to look like the Fourth of July.
Killing Cancer... And Making a Killing Too
If your first instinct is to think, "this stock must be headed for the moon," I couldn't agree more. In fact, the company is already making millions for shareholders.
That's because this company is indisputably the world's best at treating - and killing - cancerous tumors. And despite the firm's enormous profit margins, there isn't a single company in the U.S. that poses a competitive threat. Not one.
And there won't be, either. The company's products - built exclusively with state-of-the-art medical technology - cost $1.7 million each.
Why so much?
Their patented system uses digital technology and computer-generated images to aim powerful radiation beams at cancerous tumors. Unlike traditional radiation therapy, however, this company's system avoids damaging healthy organs and tissue near the tumor. And the company's products are so precisely engineered that they can sculpt beams to fit specific areas, as well as modulate the intensity of the beams for different types of tumors.
Very soon the company will unveil an upgrade to existing technology that will even let radioactive beams adjust to body movements as a patient breathes. It's that precise.
"Already the company's profit growth puts it in the top 2% of all publicly traded companies in the U.S."
The intense regulation of the healthcare industry, the complexity of the technology and the cost of the machines - which can only be produced at $1.7 million each when manufactured in huge quantities - have formed a protective moat around this company.
That means a lot to us as early investors. Because it means our investment is safe. And our profits are secure.
Already the company's profit growth puts it in the top 2% of all publicly traded companies in the U.S. And with a current order backlog of more than $900 million, things are set to get a whole lot better.
Because of continued strong demand for the company's oncology products, earnings will soar in the weeks and months ahead.
But there is yet another important reason to own this stock right now. The company is about to get an additional kicker from the Department of Homeland Security.
This Company Defeats Cancer... And Terrorists Too
On a personal level, the biggest threat we face as individuals is a cancer diagnosis.
But - as you know - on a national scale, we face a far bigger threat: terrorist acts designed to kill hundreds or perhaps thousands of innocent people. After 9/11 - and with the advent of the Department of Homeland Security - millions of dollars will be paid to those with the proven ability to prevent such attacks. Incredibly, this medical technology company is doing just that - preventing terrorist attacks - right this minute. And has a 100% success rate.
The same breakthrough medical technology that allows this company's products to see inside your body, also allows inspectors to see through 17 inches of steel.
According to the U.S. Customs Service, 6 million cargo containers arrive through 361 U.S. seaports each year. Ninety percent of the trade goods brought into the U.S. each year - some 2 billion metric tons worth - enter the country this way.
"This company has invented a "silver bullet" that defeats cancer and foils terrorist attacks."
And less than 2% of the containers are ever opened and inspected by Customs Service officials.
It's not hard to imagine these containers being used for smuggling contraband - even a potential weapon of mass destruction. Yet to physically open each container, extract the contents, and inspect the contents by hand would be time-consuming and unrealistic.
Be Sure to Register for The Investment U E-Letter
In Just 20 Minutes a Week You Can Become
More Market Savvy than 99% of Investors
Register here for your FREE Investment U online advisory. The Investment U E-Letter will help you beat the markets and stay on the path to financial independence. Twice weekly, renowned editor Dr. Steve Sjuggerud uncovers hidden market indicators, time-tested investing techniques and current emerging trends. You get action-oriented, reliable advice that will make you a smarter investor--fast. You have nothing to lose - but a wealth of proven, effective investment secrets to gain. There is no obligation. You can begin your FREE subscription to The Investment U E-Letter by entering your e-mail address below and clicking "Subscribe".
Investment U will never sell, rent or otherwise abuse your email address. It will be used solely for the purpose of sending you the Investment U E-Letter and Updates about Investment U. Should you wish to unsubscribe at any time, instructions are included with each email for immediate removal from the Investment U E-Letter subscriber file.
Not to mention unnecessary. Because this same medical technology company has developed a product that works like a giant airport baggage screening system. And can generate steel-piercing X-rays that see through container walls and allows contraband nowhere to hide.
At heart, the technology is quite simple. Electronic images are captured and transmitted to a computer monitor at an operator's station. The machine can scan a full container the size of a tractor trailer in less than three minutes. In short, it's practical, efficient and cost-effective.
The Department of Homeland Security may soon come knocking on their door with a major order. And that will turn this smaller part of their business into something very big. The effect on the stock should be tremendous.
If this firm gets a major defense-related contract, the stock will gap up immediately.
And that could happen at almost any time. Right now we have a gaping hole in national security. Dockworkers know it. Terrorists know it. So do U.S. government officials.
The head of Homeland Security, and President Bush are not going to let this vulnerability continue. And, fortunately, Congress is willing to put up the money to guarantee it.
With this company's products already screening cargo in one U.S. port and dozens of others around the world, it's my belief that it's only a matter of time before they're tapped for the big national security job.
When management reports that the company's products have been chosen by the federal government to help provide security at the nation's seaports, the stock won't just rise. It will look like something coming off the launch pad at the Kennedy Space Center.
Let me emphasize that this announcement has not been made yet.
However, I believe it will be in the coming weeks. That's why I'm sending you this letter today. So you have a chance to profit, along with the rest of the members of our financial fellowship.
Crucial Intelligence... Enormous Profits
Let me put this special opportunity in perspective.
Maybe once in a generation a company comes along that is not only wildly successful, but actually changes our way of life.
Forty years ago, it was IBM. Thirty years ago, it was Wal-Mart. And nearly twenty years ago, it was Microsoft.
"When management reports that the company's products have been chosen by the federal government to help provide security at the nation's seaports, the stock won't just rise. It will look like something coming off the launch pad at the Kennedy Space Center."
Early investors in these companies did not become millionaires. They became billionaires. And even investors who took a very small stake had their financial lives completely transformed.
Now history is repeating itself.
And everything you need to know about this company - which you can quickly buy through your existing broker - is plainly and simply spelled out in our latest special report: "Payoff of a Lifetime: A Company That Fights Cancer & Terrorism Too."
This special "white paper" details all our crucial intelligence on this unique investment opportunity. It's part of a special bonus you'll receive when you sign up for a one-year membership in the investment organization I head, The Oxford Club.
Membership in this club will allow you to receive regular updates on the status of this special investment, as it already tops our list of recommended investments. You'll get regular updates on the stock as your portfolio swells in size. And you'll also learn the proprietary system we use that protects both our profits and our principal on our investments - guaranteed.
However, in joining this well-connected group of investors, you'll receive other benefits you can't put a price on . . .
A "Life-Changing" Experience
The Oxford Club is not another financial newsletter or advisory service. Membership is by invitation only. We're extending this invitation because we have reason to believe you're someone who understands that it's difficult to profit from mainstream advice alone - and that you'd welcome an organization that's independent... unbound by convention and mainstream ideals... and committed to revealing the deeper secrets of creating and growing wealth under any circumstances.
"I am happy with the results of my investments this calendar year (an 83% increase in my portfolio) based solely on The Oxford Club's recommendations."
~ Steve Husbands
The Oxford Club is an organization like no other. And I would like to share with you our substantial intellectual resources, our deep and serious financial network, and our analysts who are diligent and extremely sophisticated. And unlike Wall Street firms, we have no conflicts of interest. We don't do investment banking deals that cloud our objectivity. We don't hawk investments for fees and commissions. We're not interested in "capturing your assets."
Our only obligation is to our members.
As a result, we don't offer an endless stream of "hot tips." Rather, we carefully research thousands of publicly-traded securities to distill the handful of opportunities that are truly worthwhile. And then we group these few winners into one of our select portfolios.
For instance, the medical technology company I'm writing you about is currently #1 in our Oxford Trading Portfolio. This portfolio is made up of the most promising individual securities in the market. Each with a highly unusual story. Each with enormous upside potential.
"About 19 years ago I received an invitation to join The Oxford Club. No one I checked with knew anything about you and I didn't join. In November 2002, I again received an invitation to join. I figured that if you had lasted two decades you couldn't do any worse than all the other investment gurus that helped me lose money. This time I did join and I thank you very much! After one year, EACH of my investments made following your recommendations has been profitable. The Oxford Club is the only investment advisory renewal I have made. In fact, I renewed for life."
~ Henry Rose, Member since 2002
We have other moneymakers as well. Like our Oxford All-Star Portfolio. This portfolio allows you to select investments run by the top money managers on the planet. Who are these individuals? Perhaps you'll recognize a few of their names: Warren Buffett, Bill Gross, Sam Zell, Mark Mobius, Mario Gabelli, Marty Zweig and others. If you don't know these men and their prodigious track records, you'll certainly benefit from getting better acquainted.
And don't overlook our Oxford Income Portfolio. If you're retired, planning for retirement, or just looking to boost your monthly income, you'll be delighted with the jaw-dropping yields we're earning on super safe investments. And without any stock market risk.
We even have a Gone Fishin' Portfolio for members who want to boost their returns while spending as little time as possible fiddling with their investments. This portfolio allows you to beat the market with very little risk, while you spend your time in the shade - casting a purple worm.
Of course, what matters above all else is investment performance, plain and simple. And our returns have been nothing short of spectacular. As we recently wrote to Oxford Club members:
"There are currently thirty-five positions in our Oxford Trading Portfolio. Twenty-nine of them are profitable.
"A considerable satisfaction with portfolio results has allowed me a greater benefit - peace of mind. Since my earned income years are over, this is no small matter. I'm comfortable that my investments are well guided, thanks to you." ~Stephen Fedor
In our Oxford Income Portfolio there are five positions. All of them are profitable.
In our Gone Fishin' Portfolio there are ten positions. All of them are profitable.
In our Oxford All-Star Portfolio there are six positions. One of them is slightly below our original purchase price. When accumulated dividends are included, all of them are profitable.
This is all the more remarkable when you consider the S&P 500 is down 0.69%% year-to-date, and up only 3.59% ove the last 2.5 years."
But there is still more that our group offers. We show you how to save thousands of dollars with your investments, including sensible advice on how to avoid Wall Street's outlandish fees, cut your investment costs to the bone, and eliminate capital gains taxes.
The Most Important Financial Alliance
You Will Ever Make
If such an association appeals to you, I invite you join us. And, of course, begin by receiving our new special report "Payoff of a Lifetime: A Company That Fights Cancer & Terrorism Too."
And please don't overlook the many additional benefits you're entitled to as a new member of The Oxford Club. Here's what you'll soon be receiving:
"The Oxford Club meeting in NYC was excellent. Each of the presenters offered valuable information about the Club and choices we have for protecting and growing our assets. I've paid much more for much less. Truth is, I've attended entire seminars that offered less value than just this 4-hour regional meeting. And the regional meeting was free to members! Another unexpected Oxford Club benefit. Thank you." ~Catherine Wynkoop, Pound Ridge, NY
The Communiqué... the official "letter of record" for Oxford Club members. Twice each month you'll learn about new investments the Club is recommending and get updates on our current portfolio. You'll also be introduced to new investment techniques and strategies - strategies and techniques that will help you become a better, more knowledgeable and wealthier investor. You'll also find wealth-building insights from market experts, traders, and company insiders. One of the most important sections of The Communiqué is the "What To Do With Your Money Today" page, which is a frank and concise discussion about which investments will profit most in the days and weeks ahead. You'll receive The Communiqué the first and fifteenth of every month - plus we'll alert you by e-mail when it's available to members "on line".
"Just a line to thank you for the good recommendations for this year. I am up about 25% for my total assets and over 30% on my assets that were sitting in Money Market accounts. I have learned a lot by being an Oxford Club member. All of the people who contribute are solid analysts. I have taken financial letters for twenty years and never made any money until I came upon the Oxford Club and the talented people on the staff. I do not usually send anyone any thank you messages until now."
The Communiqué will also keep you apprised of Club happenings, events, meetings and news from our financial network, as well as personal notices from fellow members. In fact, you can place one FREE listing each year yourself. This is an excellent vehicle for buying and selling real estate, finding loans or grants, meeting business partners, getting or offering investment and legal advice, and more.
If The Communiqué were the only benefit you received from the Club you'd be far wealthier because of it. But there's so much more . . .
Members-Only Clubhouses on 3 Continents...
One of the unique privileges of Oxford Club membership is that you always have a "place to visit" when your travels take you near one of our four global locations. There's our U.S. headquarters - a beautifully-restored historic brownstone in the heart of Baltimore's Mount Vernon district.
There's our London office in the bustling Fleet Street district. In Paris you can visit our office on the River Seine, just steps away from Notre Dame Cathedral. Or you can take the train a few hours south to our 17th century château in the French countryside, enjoy authentic French cuisine, walk our miles of tended trails, visit the local towns and take in a wine tour.
For a special treat, you might want to fly down to Central America and spend a few relaxing nights at our brand new members clubhouse retreat located directly on one of the most beautiful beaches you'll find on the Pacific coast. As an Oxford Club member, these clubhouses are yours to use and enjoy.
"I have been receiving solicitations from the OC for many years. All the while my financial advisor and my broker and my pension fund administrators managed to lose a significant portion of my money. So I fired them all and joined The Oxford Club. Hey I figured you could not possibly do worse than them. I admit that I was timid and mistrustful (can you blame me!) at the beginning. Then I started following your recommendations. Lo and behold my investments are actually making, not losing, money. For example I doubled my money on Netflix. I am significantly ahead in all the other recommendations. This is a whole new experience for me. Keep up the good work. And thanks."
~G. Ibrahim, M.D.
Wealth Report Library and Special Investors' Reports... Over the years, The Oxford Club has uncovered many powerful investment techniques and strategies that we feel every member should know about. That's why as soon as you join, we'll send you a library of information that we believe is vital to your financial success - like our report on how to get enormous profits on the best asset class of the last 10 years. There's also a special report on how to trade with the
insiders... another on a strategy many top investors use to trade fast-rising "momentum" stocks... another on the wildly successful covered call strategy we're using to buy stocks cheaper than everyone else... another still on the two most profitable secrets of the world's greatest investors.
Be sure to get all the details on the reports you'll receive on the back of your invitation form I've enclosed for you. But besides your initial library, you can download additional reports from our web site. Everytime we publish a report, we post it to our site for all members to access.
"I have been a subscriber to The Oxford Club for a couple of months now, and recently I subscribed to Steve's Against the Crowd Options service. But the largest returns that I have made up to this point have been from news contained in your Oxford Insight broadcasts. More specifically, the 2 broadcasts highlighting Netflix and Newmont Mining. In both cases, I purchased front month out-of-the-money call options 3-5 days prior to their quarterly earnings announcements, and sold the day after the announcement (in the case of Netflix) or later that same day (in the case of Newmont). With seemingly low risk, my returns were 400% and 200%, respectively!"
~Greg A. Dunsworth
Members Liaison - Pick Up The Phone and Talk to a Research Assistant... Need information on deferring taxes? Want to talk to someone about setting up an offshore account, asset protection plan or privacy strategy? Need information on estate planning? Interested in the safest and most secure way to buy precious metals ... the best and cheapest way to buy stocks on line... how to buy and sell a business? Or do you simply want to have a "real voice" explain one of our professional trading strategies to you? While we can't provide individual financial advice, virtually any financial question you have can be researched on your behalf by one of our member representatives. It's like having your own team of assistants a phone call away!
The Oxford Insight - Real-Time Market Information Directly From Investment Director, Alexander Green, Twice-Weekly... This is one of my favorite benefits of membership because it's a chance for our Investment Director to write directly to members about what's effecting our investments that day. If there's a fast-breaking opportunity that's come up, he'll pass it on. If the market has turned wacky on us - he'll let you know if there's cause for concern and what you can do immediately to protect yourself.
He'll tell you about any interesting conversations he's had recently with Wall Street bigwigs, company insiders and other trading experts. He likes to write the Insight as if you and he are sitting down to a private dinner - and he's passing on all the best stuff he's come across in the past few days. So don't forget to include your e-mail address when you fill out your membership acceptance form. The Oxford Insight is delivered by e-mail only.
"I should write more often to tell you how well our investments are doing. Thanks to your advice... I keep telling my wife how well I'm doing for us in the stock market. I must admit she knows you guys get a lot of the credit. Thanks."
Members-Only Web site... Oxford Club members are busy people - and we understand that you can't always be home when important financial news is breaking. That's why every Oxford Club member receives a very important password - one to the members-only website. With this password you can gain immediate up-to-the-minute access to new recommendations, quick trades and other information vital to your wealth from anywhere in the world.
Global Investment Expeditions, Retreats and Symposiums... Perhaps no group is as adventurous as The Oxford Club. That's why we're forever traveling the world in search of new business and investment opportunities.
"I have been following your advice since last November and it has been profitable. I have learned more about asset allocation and developing a sensible attitude about risk in the past 8 months than in the previous 45 years, many of which were spent as a series 7 broker."
Our travels have taken us to such places as the Caribbean, the Far East, New Zealand, Central and South America, South Africa, Iceland - and everywhere we go we make invaluable connections with leaders of industry, entrepreneurs, and heads of state. Besides all the fun, camaraderie and adventure, profits have a habit of following us. One story we like to tell is the time one of our members was so impressed with a company she visited in Hong Kong that she telephoned her broker immediately to buy it. By the time she arrived home - the stock had tripled!
Local Chapter Meetings, Where We Come To You... Last year, The Oxford Club sponsored several chapter meetings in towns and cities across America. It's one of the ways we bring the many benefits of membership to you. These events give you an opportunity to get the latest news on investments, hear experts speak about important financial matters, learn about new money-making opportunities, get asset protection advice, form strategic alliances and, of course, meet fellow members in your town. You'll find upcoming meetings listed in your twice-monthly Communiqué - and one phone call reserves your spot.
"I'm calling to thank you. My portfolio, thanks to The Oxford Club, is up over 22% year to date, and up over 252% over the last 12 months. Keep up the good work."
~ Edward Bayliss
And that's just for starters... There are literally dozens more entitlements Oxford Club members enjoy... like the annual scholarship available exclusively to members' children... Investment U - a 3-day crash course in professional investment techniques... Pillar One Partnerships, where you enjoy substantial discounts off of a host of financial services... our Members' Exchange Program, where you can connect with other members looking to partner in business deals, buy or sell real estate, arrange financing deals and more . . .
Special Offer... Join Now for as Little as $49!
No question, with all these benefits - all these opportunities to profit - you're probably thinking our special report "Payoff of a Lifetime: A Company That Fights Cancer & Terrorism Too" - and membership in The Oxford Club - must cost several thousand dollars. After all, the intelligence on this one opportunity alone is worth that. But you'll be surprised to learn that you will receive all the benefits I've mentioned here and more - for just $79. Membership regularly costs $149, but with this offer, you get nearly half off. (Or, if you prefer, you can take a trial membership for just $49 a year.)
I know this fee seems preposterously low for intelligence that can have such a profound impact on your financial life... and I don't blame you if the low price leaves you thinking, there's got to be some kind of catch... But let me assure you - there isn't. We've priced this special offer so low because we want to encourage membership, not discourage it.
So, you get everything I've mentioned to you in this letter and more, "Payoff of a Lifetime: A Company That Fights Cancer & Terrorism Too"; all our best investment recommendations; 24 twice-monthly issues of The Communiqué, the 7 wealth reports described on the membership acceptance form, access to our Clubhouses worldwide, web site and a direct line to our Members Liaison office, and the dozens of other benefits that come with The Oxford Club's "Premiere" membership.
Every week I talk to hundreds of investors who lost thousands of dollars in the grinding 3 year bear market from 2000 to 2002. You can risk that kind of money yourself in the years ahead... or you can lay those fears to rest right now. And get on with the important task of building a legacy of lasting wealth.
All the information you need is in our special report "Payoff of a Lifetime: A Company That Fights Cancer & Terrorism Too," along with the host of valuable information you'll recieve as a member of The Oxford Club. Consider it your first meaningful step toward financial independence. (And please don't forget to share this crucial intelligence with your children and grandchildren.)
You now have an opportunity to turn a small stake into a lifetime of profits. For this reason, I urge you to request and read this special report as soon as possible. You can click below to fill out your membership acceptance form online to receive the report and activate your membership right now.
James Boxley Cooke
The Oxford Club
P.S. It's only a matter of time before the national media and Wall Street realize this incredible opportunity. When that happens, millions of investors - and their fund managers will be shoveling money into this stock. Right now, you have a groundfloor investment opportunity, so don't delay. Sign up today to activate your membership. We'll e-mail you this report immediately and we'll send you a hard copy - along with all the other reports promised - via priority mail in your new member welcome package.
|RecommendKeepReplyMark as Last ReadRead Replies (1)|
|To: StockDung who wrote (940)||3/22/2005 1:33:27 PM|
|Hyperbole Made Easy|
Whaling had its Melville, bullfighting had its Hemingway. Limitless financial opportunity has Agora Publishing, which puts out The Oxford Club and True Wealth newsletters. Nobody writes a better investment tease. The language in which riches are promised in two recent mailings from The Oxford Club and True Wealth is so ripe and over the top it's precious.
Cleans windows, too
The Oxford Club's effort begins by appropriating every investor's most ardent fantasy: a company that cures cancer and combats terrorism. In heavy-breathing, highly misleading fashion, the mailer announces that "silver bullet that conquers nature's deadliest disease is about to 'go public.'" (This stock, I later learn, "went public" more than 40 years ago.) "Now there is only a brief window -- perhaps just weeks -- before these shares blast off." It gets better. Owning this stock will be like having "a winning lottery ticket." The pitchman, Oxford chairman James Boxley Cooke, says this "may be the best single-stock idea I've seen in my lifetime as an investor." No need to compare this stock to Microsoft because, well, it's better.
Then comes the terrorism kicker. A related company technology can screen cargo at ports or airports. At any moment, says Cooke, the company could get a big contract from the Department of Homeland Security. And when it does, "the stock won't just rise. It will look like something coming off the launch pad at the Kennedy Space Center." Intrigued -- and then some -- I send for a special report on the company. I pay $49.
Then I download the report, and I'm immediately deflated. The mystery stock is Varian Medical Systems, a fine New York Stock Exchange company with revenues of $1.2 billion, making it scarcely unknown. In fact, the stock has risen 800% since January 1999. I ask Spencer Sias, Varian's head of corporate communications and investor relations, what he thinks of Oxford's pitch. "It made me wince," he says.
I ask Sias about Varian Medical's counterterrorism prospects. "I wouldn't buy our stock because of cargo screening," he says. "Right now, we have a $20-million to $25-million business selling accelerants to companies that screen cargo. We are working on a prototype of a product that would allow screening to work without disrupting the flow of trade." Revenues from that product might not show up until 2006 or 2007, if ever.
Okay, so you pass on Varian. The mailer from True Wealth describes something that was "outlawed for 41 years -- Now LEGAL again." No, it isn't sodomy in Georgia. The investment allegedly "launched the largest family fortune the world has ever seen." This "currency" could "return 665% in the next 12 months." And then the letter goes on to make my favorite investment claim of all time: Pay to find out what the secret currency is (I'm thinking drachmas, ringgit or yak teeth) and you can then use the secret "to make as much money as you want." Could it be a printing press?
No, the "secret currency" is gold coins, which have been "legal again" for 30 years. After paying $49.50, I'm deflated once more. Saint-Gaudens gold coins, favored by True Wealth, lost almost 80% of their value after 1989. To state the obvious, when you buy gold coins, you're speculating, not investing.
Wait, there's more. The letter says subscribers will be shown a way to buy the coins at a 30% discount, "which means you could buy today and sell tomorrow -- and pocket as much as a 30% gain." Yes, if you find an incredible sucker. Simply put, the coins are sold by dealers at a discount to their "retail price." If you can then find anyone who will pay you "retail," you're golden.
Columnist Andrew Feinberg writes about the choices, challenges and frustrations facing individual investors.
|RecommendKeepReplyMark as Last ReadRead Replies (12)|